AstraZeneca PLC (AZN)
64.25
+1.05
(+1.66%)
USD |
NASDAQ |
Nov 21, 16:00
64.28
+0.03
(+0.05%)
After-Hours: 17:40
AstraZeneca Enterprise Value: 221.25B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 221.25B |
| November 19, 2024 | 223.11B |
| November 18, 2024 | 221.84B |
| November 15, 2024 | 221.35B |
| November 14, 2024 | 226.96B |
| November 13, 2024 | 227.73B |
| November 12, 2024 | 227.42B |
| November 11, 2024 | 226.18B |
| November 08, 2024 | 225.25B |
| November 07, 2024 | 225.87B |
| November 06, 2024 | 223.27B |
| November 05, 2024 | 230.77B |
| November 04, 2024 | 246.77B |
| November 01, 2024 | 246.74B |
| October 31, 2024 | 245.90B |
| October 30, 2024 | 251.11B |
| October 29, 2024 | 258.52B |
| October 28, 2024 | 260.97B |
| October 25, 2024 | 258.00B |
| October 24, 2024 | 260.63B |
| October 23, 2024 | 263.89B |
| October 22, 2024 | 265.03B |
| October 21, 2024 | 265.41B |
| October 18, 2024 | 267.95B |
| October 17, 2024 | 267.20B |
| Date | Value |
|---|---|
| October 16, 2024 | 268.10B |
| October 15, 2024 | 266.68B |
| October 14, 2024 | 267.45B |
| October 11, 2024 | 265.13B |
| October 10, 2024 | 263.64B |
| October 09, 2024 | 265.61B |
| October 08, 2024 | 263.64B |
| October 07, 2024 | 263.64B |
| October 04, 2024 | 265.50B |
| October 03, 2024 | 266.92B |
| October 02, 2024 | 272.04B |
| October 01, 2024 | 269.22B |
| September 30, 2024 | 266.86B |
| September 27, 2024 | 265.97B |
| September 26, 2024 | 267.70B |
| September 25, 2024 | 265.72B |
| September 24, 2024 | 263.64B |
| September 23, 2024 | 264.48B |
| September 20, 2024 | 268.32B |
| September 19, 2024 | 269.94B |
| September 18, 2024 | 268.95B |
| September 17, 2024 | 268.79B |
| September 16, 2024 | 270.37B |
| September 13, 2024 | 267.98B |
| September 12, 2024 | 270.12B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
111.98B
Minimum
Mar 16 2020
296.97B
Maximum
Aug 30 2024
203.91B
Average
215.55B
Median
Mar 02 2022
Enterprise Value Benchmarks
| GSK PLC | 84.49B |
| Amgen Inc | 206.13B |
| Johnson & Johnson | 384.09B |
| Sanofi SA | 136.14B |
| Moderna Inc | 7.348B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.429B |
| Revenue (Quarterly) | 13.56B |
| Total Expenses (Quarterly) | 11.46B |
| EPS Diluted (Quarterly) | 0.455 |
| Gross Profit Margin (Quarterly) | 77.29% |
| Profit Margin (Quarterly) | 10.53% |
| Earnings Yield | 3.25% |
| Operating Earnings Yield | 5.36% |
| Normalized Earnings Yield | 3.855 |